GSK plc announced on June 13, 2025, that the EMA has accepted its application to expand the use of its RSV vaccine, Arexvy, for adults 18 and older, with a decision expected in H1 2026. The vaccine is currently approved for adults 60+ and those 50-59 at increased risk, addressing a common virus affecting 64 million people globally each year.